Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis

Table 1 Characteristics of the studies included in the NMA

Study	Country	Published year	Study design	Treatment arms	Patient number	Discontinued patients	Intervention duration
Numakura [24]	Japan	2022	2-arm RCTs	1.Placebo 2.Levofloxacin	51 55	4 5	6 weeks
Kamali [29]	Iran	2020	4-arm RCTs	1.Placebo 2.Celecoxib 3.Phenazopyridine 4.Oxybutynin	30 30 30 30	0 0 0 0	6 weeks
Serretta [28]	Italy	2010	2-arm RCTs	1.Placebo 2.Prulifloxacin	22 21	1 3	6 weeks
Damiano [27]	America	2009	2-arm RCTs	1.Placebo 2.Prulifloxacin	35 37	12 7	6 weeks
Colombel [26]	France	2006	2-arm RCTs	1.Placebo 2.Ofloxacin	58 57	20 9	9 weeks
Al Khalifa [25]	Canada	2000	2-arm RCTs	1.Placebo 2.Isoniazid	80 80	9 7	6 weeks

ISSN: 1471-2490